» Articles » PMID: 24931170

Targeting WNT1-inducible Signaling Pathway Protein 2 Alters Human Breast Cancer Cell Susceptibility to Specific Lysis Through Regulation of KLF-4 and MiR-7 Expression

Overview
Journal Oncogene
Date 2014 Jun 17
PMID 24931170
Citations 39
Authors
Affiliations
Soon will be listed here.
Abstract

The molecular basis for the resistance of tumor cells to cell-mediated cytotoxicity remains poorly understood and thus poses a major challenge for cancer immunotherapy. The present study was designed to determine whether the WNT1-inducible signaling pathway protein 2 (WISP2, also referred to as CCN5), a key regulator of tumor cell plasticity, interferes with tumor susceptibility to cytotoxic T-lymphocyte (CTL)-mediated lysis. We found that silencing WISP2 signaling in human breast adenocarcinoma MCF7 cells impairs CTL-mediated cell killing by a mechanism involving stem cell marker Kruppel-like factor-4 (KLF-4) induction and microRNA-7 (miR-7) downregulation. Inhibition of transforming growth factor beta (TGF-β) signaling using the A83-01 inhibitor in MCF7-shWISP2 cells resulted in a significant reversal of the epithelial-to-mesenchymal-transitioned (EMT) phenotype, the expression of KLF-4 and a partial recovery of target susceptibility to CTLs. More importantly, we showed that silencing KLF-4 was accompanied by a reduction in MCF7-shWISP2 resistance to CTLs. Using human breast cancer tissues, we demonstrated the coexpression of KLF-4 with EMT markers and TGF-β pathway signaling components. More importantly, we found that KLF-4 expression was accompanied by miR-7 inhibition, which is partly responsible for impairing CTL-mediated lysis. Thus, our data indicate that WISP2 has a role in regulating tumor cell susceptibility through EMT by inducing the TGF-β signaling pathway, KLF-4 expression and miR-7 inhibition. These studies indicate for the first time that WISP2 acts as an activator of CTL-induced killing and suggests that the loss of its function promotes evasion of immunosurveillance and the ensuing progression of the tumor.

Citing Articles

KLF4: a multifunctional nexus connecting tumor progression and immune regulation.

Ju Y, Xiao W, Mathis B, Shi Y Front Immunol. 2025; 16:1514780.

PMID: 39995670 PMC: 11848521. DOI: 10.3389/fimmu.2025.1514780.


Eribulin is an immune potentiator in breast cancer that upregulates human leukocyte antigen class I expression via the induction of NOD-like receptor family CARD domain-containing 5.

Wada A, Hirohashi Y, Kutomi G, Murata K, Iwabuchi S, Mizue Y Cancer Sci. 2023; 114(12):4511-4520.

PMID: 37991442 PMC: 10728009. DOI: 10.1111/cas.15986.


EMT-induced immune evasion: connecting the dots from mechanisms to therapy.

Imodoye S, Adedokun K Clin Exp Med. 2023; 23(8):4265-4287.

PMID: 37966552 DOI: 10.1007/s10238-023-01229-4.


The loss of B7-H4 expression in breast cancer cells escaping from T cell cytotoxicity contributes to epithelial-to-mesenchymal transition.

Zhou L, Wu J, Ruan M, Xiao Y, Lan H, Wu Q Breast Cancer Res. 2023; 25(1):115.

PMID: 37794509 PMC: 10548745. DOI: 10.1186/s13058-023-01721-5.


Hypoxia, a Targetable Culprit to Counter Pancreatic Cancer Resistance to Therapy.

Abou Khouzam R, Lehn J, Mayr H, Clavien P, Wallace M, Ducreux M Cancers (Basel). 2023; 15(4).

PMID: 36831579 PMC: 9953896. DOI: 10.3390/cancers15041235.


References
1.
Chouaib S . Integrating the quality of the cytotoxic response and tumor susceptibility into the design of protective vaccines in tumor immunotherapy. J Clin Invest. 2003; 111(5):595-7. PMC: 151911. DOI: 10.1172/JCI18044. View

2.
Mani S, Guo W, Liao M, Eaton E, Ayyanan A, Zhou A . The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008; 133(4):704-15. PMC: 2728032. DOI: 10.1016/j.cell.2008.03.027. View

3.
Dunn G, Bruce A, Ikeda H, Old L, Schreiber R . Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002; 3(11):991-8. DOI: 10.1038/ni1102-991. View

4.
Verhaak R, Hoadley K, Purdom E, Wang V, Qi Y, Wilkerson M . Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010; 17(1):98-110. PMC: 2818769. DOI: 10.1016/j.ccr.2009.12.020. View

5.
Frewer K, Sanders A, Owen S, Frewer N, Hargest R, Jiang W . A role for WISP2 in colorectal cancer cell invasion and motility. Cancer Genomics Proteomics. 2013; 10(4):187-96. View